In recent years, with groundbreaking innovations in China's medical technology and the continuous enrichment of medical resources, China is transitioning from a "medical powerhouse" to a "global leader in healthcare." It has become a vital destination for international patients with complex and severe illnesses seeking hope.

In 2024, the Thoracic Oncology Department of Beijing GoBroad Hospital provided medical services to patients from Kazakhstan, the Middle East, Russia, and other countries. To enhance the medical experience for international patients, the department actively engages in multicultural training and language skill development. These cross-border medical stories embody the breakthroughs and advancements of the hospital's international medical service system.

Multidisciplinary Collaboration: A Lifeline for Critical Cases

Nawal, a patient from the Middle East, faced severe spinal cord compression due to multiple bone metastases and an acute pathological fracture of the C3 cervical vertebra after thoracic tumor surgery, putting her at risk of high-level paralysis. Due to limitations in local medical technology, she and her family traveled thousands of miles to Beijing GoBroad Hospital.

In response to this complex case, the hospital swiftly assembled experts from the Oncology, Spine Surgery, Radiotherapy, Anesthesiology, and Molecular Diagnostics departments for a multidisciplinary team consultation (MDT). During an 8-hour high-risk surgery, the team successfully relieved the spinal cord compression, avoiding paralysis and significantly reducing her severe pain. Upon discharge, Nawal expressed her gratitude: "Your care and dedication gave me back my health."

New Drug, No Waiting: Delivering China’s Breakthroughs to Global Patients

Kirill, a 36-year-old from Russia, was diagnosed with KRAS G12C-mutated advanced non-small cell lung cancer with multiple nodules in both lungs, suspected as metastatic tumors. Traditional treatments were ineffective, leaving him in despair. After learning about Furazercib (developed by Innovent Biologics), the first Chinese-developed targeted drug for KRAS G12C, which was approved by the NMPA on August 21, 2024, he sought treatment at Beijing GoBroad Hospital.

Under the evaluation of Director Qin Haifeng from the Thoracic Oncology Department, Kirill was deemed eligible for the therapy. Remarkably, only 10 days passed from drug approval to his first prescription, making him one of the world's first international patients to benefit from this innovative treatment. After two months, follow-up evaluations showed partial remission (PR) with reduced tumor burden. "Here, I witnessed the speed and warmth of medical advancement," Kirill remarked.

Breaking Barriers in Advanced Cancer: Minimally Invasive Interventions

Aydin, a patient from Kazakhstan, arrived at Beijing GoBroad Hospital after exhausting multiple lines of treatment for nasopharyngeal cancer with liver and lung metastases. The Interventional Oncology Team initiated a multidisciplinary consultation and formulated a personalized arterial infusion chemotherapy and hepatic arterial chemoembolization plan. This targeted, high-concentration local therapy effectively controlled his cervical masses and liver metastases, significantly improving his quality of life. "GoBroad gave me hope when I thought all paths were closed," Aydin shared during a follow-up.

With cutting-edge medical technology, innovative treatment strategies, and superior international services, GoBroad remains committed to overcoming geographical and language barriers, offering new hope for patients worldwide.